Antineoplastics
1
Reactions 1363 - 6 Aug 2011 S Antineoplastics Myelosuppression: 13 case reports Eight female and five male patients aged 5–28 years developed myelosuppression [see table] during neoadjuvant treatment with antineoplastics for nongerminomatous germ cell tumours [routes and durations of treatment to onset of reactions, and outcomes not stated]. Patients received one of three chemotherapy regimens in combination with radiotherapy: either cisplatin 20 mg/m 2 and etoposide 60 mg/m 2 for 5 days in a row; or carboplatin 450 mg/m 2 on day 1 with etoposide 150 mg/m 2 days 1–3; or ifosfamide 900 mg/m 2 , cisplatin 20 mg/m 2 and etoposide 60 mg/m 2 for 5 consecutive days. Patients 3, 4, 6, 7, 9–11, and 13 had dosage reductions of 20–50%. Patients 1 and 8 had their second courses of therapy delayed, and patient 12 had autologous haematopoietic cell rescue between cycles two and three. Patient characteristics Pt/sex/ Drugs WBC Platelet Treatments age (y) grade* grade* 1/F/9 Cisplatin/etoposide 4 0 GCSF 2/F/5 Cisplatin/etoposide 3 0 - 3/M/9 Cisplatin/etoposide 3 0 - 4/F/5 Carboplatin/ 4 4 GCSF; etoposide platelets 5/M/19 Ifosfamide/cisplatin/ 3 3 GCSF etoposide 6/M/11 Ifosfamide/cisplatin/ 4 1 GCSF; etoposide platelets 7/F/28 Ifosfamide/cisplatin/ 4 4 GCSF etoposide 8/F/8 Cisplatin/etoposide 2 1 - 9/F/12 Cisplatin/etoposide 3 0 GCSF 10/M/12 Ifosfamide/cisplatin/ 3 1 GCSF; etoposide platelets 11/M/10 Ifosfamide/cisplatin/ 4 4 GCSF; etoposide platelets 12/F/12 Ifosfamide/cisplatin/ 4 4 GCSF; etoposide platelets 13/F/16 Ifosfamide/cisplatin/ 4 4 GCSF; etoposide platelets * Adverse reaction grade assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. Nakamura H, et al. Evaluation of neoadjuvant therapy in patients with nongerminomatous malignant germ cell tumors. Journal of Neurosurgery: Pediatrics 7: 431-8, No. 4, Apr 2011 - Japan 803058375 1 Reactions 6 Aug 2011 No. 1363 0114-9954/10/1363-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Antineoplastics
Reactions 1363 - 6 Aug 2011
SAntineoplastics
Myelosuppression: 13 case reportsEight female and five male patients aged 5–28 years
developed myelosuppression [see table] duringneoadjuvant treatment with antineoplastics fornongerminomatous germ cell tumours [routes anddurations of treatment to onset of reactions, and outcomesnot stated].
Patients received one of three chemotherapy regimens incombination with radiotherapy: either cisplatin 20 mg/m2
and etoposide 60 mg/m2 for 5 days in a row; or carboplatin450 mg/m2 on day 1 with etoposide 150 mg/m2 days 1–3;or ifosfamide 900 mg/m2, cisplatin 20 mg/m2 and etoposide60 mg/m2 for 5 consecutive days. Patients 3, 4, 6, 7, 9–11,and 13 had dosage reductions of 20–50%. Patients 1 and 8had their second courses of therapy delayed, and patient 12had autologous haematopoietic cell rescue between cyclestwo and three.
Patient characteristicsPt/sex/ Drugs WBC Platelet Treatmentsage (y) grade* grade*
1/F/9 Cisplatin/etoposide 4 0 GCSF2/F/5 Cisplatin/etoposide 3 0 -3/M/9 Cisplatin/etoposide 3 0 -4/F/5 Carboplatin/ 4 4 GCSF;
etoposide platelets5/M/19 Ifosfamide/cisplatin/ 3 3 GCSF
etoposide6/M/11 Ifosfamide/cisplatin/ 4 1 GCSF;
etoposide platelets7/F/28 Ifosfamide/cisplatin/ 4 4 GCSF
etoposide8/F/8 Cisplatin/etoposide 2 1 -9/F/12 Cisplatin/etoposide 3 0 GCSF10/M/12 Ifosfamide/cisplatin/ 3 1 GCSF;
etoposide platelets11/M/10 Ifosfamide/cisplatin/ 4 4 GCSF;
etoposide platelets12/F/12 Ifosfamide/cisplatin/ 4 4 GCSF;
etoposide platelets13/F/16 Ifosfamide/cisplatin/ 4 4 GCSF;
etoposide platelets
* Adverse reaction grade assessed according to National CancerInstitute Common Terminology Criteria for Adverse Events, version 3.
Nakamura H, et al. Evaluation of neoadjuvant therapy in patients withnongerminomatous malignant germ cell tumors. Journal of Neurosurgery:Pediatrics 7: 431-8, No. 4, Apr 2011 - Japan 803058375
1
Reactions 6 Aug 2011 No. 13630114-9954/10/1363-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
